Stock CYBN CYBIN INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Cybin Inc.

Equities

CYBN

CA23256X1006

Market Closed - Nyse
Other stock markets
 21:00:00 29/04/2024 BST 		After market 00:56:54
0.35 USD 0.00% Intraday chart for Cybin Inc. 0.345 -1.43%
04-17 Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003 MT
04-16 Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cybin to Participate at the 27th Annual Milken Institute Global Conference
BU
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
BU
Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003
MT
Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment
MT
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder
BU
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
BU
Cybin : MATERIAL CHANGE REPORT - Form 6-K
PU
Cybin : AGENCY AGREEMENT - Form 6-K
PU
Cybin Inc. announced that it has received $150 million in funding from a group of investors
CI
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas
BU
Sector Update: Health Care Stocks Softer Friday Afternoon
MT
Cybin Starts Phase 2 Proof-of-Concept Study in Generalized Anxiety Disorder
MT
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder
BU
Cybin Inc. Initiates Phase 2 Proof-Of-Concept Study of Cyb004 in Generalized Anxiety Disorder
CI
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO
AQ
Cybin Reaches Alignment With FDA on Late-Stage Design For Major Depressive Disorder Trial
MT
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
BU
Cybin Inc. Announces Positive End-Of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design
CI
Cybin Inc. - Announces Oversubscribed Private Placement of U.S. $150 Million
AQ
Sector Update: Health Care Stocks Ease Wednesday Afternoon
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYBN Stock
  4. News Cybin Inc.